Literature DB >> 6290850

Mechanism of antibody-mediated protection against herpes simplex virus infection in athymic nude mice: requirement of Fc portion of antibody.

I Hayashida, S Nagafuchi, Y Hayashi, Y Kino, R Mori, H Oda, N Ohtomo, A Tashiro.   

Abstract

Experiments were performed to investigate the resistance of the host due to antibody-mediated mechanisms to herpes simplex virus (HSV) infection. Transfer of hyperimmune anti-HSV mouse serum inhibited the development of skin lesions and prolonged the survival of lethally HSV-infected nude mice. Relatively high concentrations of antibody were required to achieve this protection. Antisera prepared in heterologous animals were also effective, while administration of anti-cowpox virus serum or interferon provided no protection. This type of protection is therefore due to specific antibody and cannot be attributed to interferon. In order to delineate the requirement for antibody in antibody-mediated protection, human gamma globulin preparations were transferred to lethally HSV-infected nude mice. Transfer of intact human gamma globulin (GG) was effective in controlling infection. S-sulfonation of GG did not diminish the protective ability. However, purified F(ab')2 did not have any protective action even when it was administered frequently to maintain serum neutralizing antibody titer. GG was effective in C5-deficient mice lethally infected with HSV. These results indicate that in vivo antibody-mediated protection to HSV infection requires the Fc region of the intact IgG molecule and suggest that antibody-dependent cell-mediated cytotoxicity may be operative in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6290850     DOI: 10.1111/j.1348-0421.1982.tb00203.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  12 in total

1.  Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells.

Authors:  K E Van Vliet; L A De Graaf-Miltenburg; J Verhoef; J A Van Strijp
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

2.  Immunological mechanisms giving rise to latency of herpes simplex virus in the spinal ganglia of the mouse.

Authors:  K E Schneweis; M Brado; B Ebers; A Friedrich; M Olbrich; W Schüler
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

3.  Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin.

Authors:  K S Erlich; R D Dix; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

4.  Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Authors:  Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

5.  A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.

Authors:  Brian Moldt; Niccole Schultz; D Cameron Dunlop; Michael D Alpert; Jackson D Harvey; David T Evans; Pascal Poignard; Ann J Hessell; Dennis R Burton
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G.

Authors:  I Frank; H M Friedman
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

7.  In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Authors:  T Nagashunmugam; J Lubinski; L Wang; L T Goldstein; B S Weeks; P Sundaresan; E H Kang; G Dubin; H M Friedman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 8.  Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.

Authors:  Mark A Brockman; David M Knipe
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

9.  Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Authors:  Xiaoqing Lin; John M Lubinski; Harvey M Friedman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries.

Authors:  P P Sanna; R A Williamson; A De Logu; F E Bloom; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.